Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future

Authors: Férir, Geoffrey; Kaptein, Suzanne; Neyts, Johan; De Clercq, Erik

Source: Reviews in Medical Virology, Volume 18, Number 1, January 2008 , pp. 19-34(16)

Buy & download fulltext article:

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Abstract:

A decade ago, standard therapy against chronic hepatitis B virus infections only consisted of lamivudine or IFN-α. Treatment with lamivudine and IFN has been compounded by, respectively, the emergence of drug-resistant virus strains and the appearance of serious side effects. In the last 10 years, hepatitis B treatment has made much progress. Several treatments are now licensed for the treatment of patients with chronic hepatitis B and others are under development. Here, we provide an overview of the potential and mode of action of anti-HBV agents that are currently available, and/or may become available in the near future. Foremost among these newer compounds are adefovir dipivoxil, entecavir and telbivudine. Copyright © 2007 John Wiley & Sons, Ltd.

Document Type: Review article

DOI: http://dx.doi.org/10.1002/rmv.554

Publication date: 2008-01-01

More about this publication?

As of January 2010, this journal will no longer be available on IngentaConnect, please visit Wiley InterScience to arrange continued access to this content
Access this journal at Wiley InterScience
ingentaconnect is not responsible for the content or availability of external websites